NCT07436234

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe SAR

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 111 (estimated)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR

Detailed description

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR. Participants will be randomized to receive AK139 regimen or placebo subcutaneous injection and followed up to week 12

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	AK139	AK139 regimen 1- subcutaneous injection.
DRUG	AK139	AK139 regimen 2- subcutaneous injection
DRUG	Placebo	Placebo-subcutaneous injection

Timeline

• Start date: 2026-03-02
• Primary completion: 2026-09-30
• Completion: 2027-05-13
• First posted: 2026-02-27
• Last updated: 2026-02-27

Locations

1 site across 1 country: China